Parameter | Number of patients | Median ERI | IQR | P-value |
---|---|---|---|---|
Primary Outcome | ||||
Residual renal function | ||||
Present | 36 | 9.5 | (7.0–15.3) | 0.45 |
Absent | 64 | 11.0 | (6.3–16.2) | |
Secondary Outcomes | ||||
Dialysis modality | ||||
HD | 67 | 10.8 | (8.5–14.3) | 0.84 |
PD | 33 | 10.2 | (5.9–16.0) | |
RAS blocker use | 52 | 11.6 | (7.9–16.7) | |
ACE inhibitor | 43 | 11.8 | (8.1–16.8) | 0.10 |
ARB | 9 | 11.0 | (6.0–13.7) | |
No RAS blocker use | 48 | 9.2 | (6.1–15.2) | |
PTH category (pmol/L) | ||||
< 17 | 19 | 13.5 | (6.5–16.8) | 0.73 |
17–76.5 | 34 | 9.6 | (6.2–14.9) | |
> 76.5 | 28 | 9.1 | (6.8–15.3) | |
Systemic inflammation | ||||
Present | 14 | 16.5 | (11.0–18.7) | <0.01 |
Absent | 86 | 9.5 | (6.0–14.9) | |
Underlying kidney disease | ||||
ESKD (cause unknown) | 66 | 10.8 | (7.8–15.4) | 0.32 |
Renal vascular disease | 14 | 8.4 | (5.2–14.3) | |
Cystic kidney disease | 4 | 6.9 | (3.9–13.2) | |
Autoimmune disease | 4 | 16.5 | (12.0–17.9) | |
Other and unknown | 12 | 9.1 | (6.4–15.5) |